Abdul Rahman Agha El Kinge | American University of Beirut (original) (raw)

Papers by Abdul Rahman Agha El Kinge

Clinical Oncology, 2007

El-Haddad G, 2004, SEMIN NUCL MED, V34, P313, DOI 10.1053-j.semnuclmed.2004.06.006; Majo J, 2001,... more El-Haddad G, 2004, SEMIN NUCL MED, V34, P313, DOI 10.1053-j.semnuclmed.2004.06.006; Majo J, 2001, CLIN ORTHOP RELAT R, P200; NAGAMINE N, 1982, CANCER, V50, P1794, DOI 10.1002-1097-0142(19821101)50:91794::AID-CNCR28205009253.0.CO;2-L; Patrikeos A, 2005, CLIN NUCL MED, V30, P617, DOI 10.1097-01.rlu.0000174235.00577.fc; PHELPS ME, 2004, PROGR ABSTR RAD SOC; Pierce JC, 2004, AM J ROENTGENOL, V183, P35; Wasyliw CW, 2005, CLIN NUCL MED, V30, P700, DOI 10.1097-01.rlu.0000178786.99368.1d

Our study goal was to evaluate the behavioral response and practices of cancer patients to the co... more Our study goal was to evaluate the behavioral response and practices of cancer patients to the coronavirus disease 2019 (COVID-19) pandemic in the Middle East and north Africa. Methods: A cross-sectional study was conducted using a validated anonymous 45-question survey administered via SurveyMonkey R to cancer patients in 13 centers in Algeria, Egypt, Jordan, Kuwait, Morocco and Saudi Arabia. Results: During the study period (from 21 April to 30 May 2020), 3642 patients participated in the study. The majority of patients (84.81%) were worried about contracting the infection. The reported strict adherence to precautions included avoiding the following actions: hand-shaking (77.40%), hugging and kissing (82.89%), social gathering (90.09%), meeting friends (84.68%) and visiting markets (75.65%). In a multivariate analysis, patients with poor precautionary practices were about twice as likely to cancel their medical appointment or a treatment session. Conclusion: Improving cancer patients' knowledge of and adherence to precautionary measures is needed not just to reduce the risk of acquiring infection but also to minimize the interruption of their medical care. Lay abstract: COVID-19 poses a higher risk for patients with cancer than other patients; therefore, it is prudent that they adhere to precautionary measures to protect themselves from the infection. We conducted a study to evaluate the behaviors and practices of these patients in response to the COVID-19 pandemic in the Middle East and ,orth Africa. We developed a survey of 45 questions that was distributed in 13 centers in Algeria, Egypt, Jordan, Kuwait, Morocco and Saudi Arabia between 21 April and 30 May 2020. About 85% of the 3642 patients who participated in the study were worried about contracting the infection. A substantial percentage of them (10-30%) were not adhering to various precautions and social distancing rules. On the other hand, 16% of them canceled medical appointments and 12% canceled treatment sessions. Our study showed the need for better adherence of patients with cancer to the infection precautions and most importantly, the need to have a better compliance with their treatment plans, such as keeping their scheduled appointments, to avoid harms from treatment delays. Future Oncol.

Oncotarget, Jan 17, 2018

Molecular profiling and functional assessment of signalling pathways of advanced solid tumours ar... more Molecular profiling and functional assessment of signalling pathways of advanced solid tumours are becoming increasingly available. However, their clinical utility in guiding patients' treatment remains unknown. Here, we assessed whether molecular profiling helps physicians in therapeutic decision making by analysing the molecular profiles of 1057 advanced cancer patient samples after failing at least one standard of care treatment using a combination of next-generation sequencing (NGS), immunohistochemistry (IHC) and other specific tests. The resulting information was interpreted and personalized treatments for each patient were suggested. Our data showed that NGS alone provided the oncologist with useful information in 10-50% of cases (depending on cancer type), whereas the addition of IHC/other tests increased extensively the usefulness of the information provided. Using internet surveys, we investigated how therapy recommendations influenced treatment choice of the oncologis...

Leukemia Research, 2009

1. Leuk Res. 2009 Apr;33(4):565-6. Epub 2008 Jun 20. Gemtuzumab Ozogamicin is a promising post-re... more 1. Leuk Res. 2009 Apr;33(4):565-6. Epub 2008 Jun 20. Gemtuzumab Ozogamicin is a promising post-remission therapy for acute myeloid leukemia. El Kinge AR, Hatoum HA, Mahfouz RA, Otrock ZK, Jabbour E, Kantarjian H ...

Leukemia research

Citation: Allen T, Khoni NS, Dunphy B, Kinge ARE, Court NB. Efficacy and safety of Specific Conju... more Citation: Allen T, Khoni NS, Dunphy B, Kinge ARE, Court NB. Efficacy and safety of Specific Conjugate Particle (SCP)-Doxorubicin in Patients with Soft Tissue Sarcoma, a Randomized Clinical Study. J Vaccine Immunotechnology. 2017;3(1): 5. Abstract Objective: Doxorubicin has been the mainstay of treatment for advanced STS. However, the conventional formulation of doxorubicin has not been used clinically, due to poor penetration of the natural physiologic barriers, poor water solubility and high side effects profile. To overcome these obstacles authors compared the use of Specific conjugate particle doxorubicin (Group 1), a proven efficacious agent with advanced technical drug, and PEGylated liposomal Doxorubicin (Group 2) in a randomized prospective Phase III trial involving patients with advanced soft tissue sarcomas. Methods: We recruited eighty-four patients (32 males and 52 females) with histologically confirmed locally advanced or metastatic Soft Tissue Sarcoma (STS). The participants were between the ages of 18 and 70 years. Patients were randomized to receive either Specific Conjugate Particle Doxorubicin (SCP-Doxorubicin) and paclitaxel or the conventionally accepted PEGylated Liposomal Doxorubicin (PEG-Doxorubicin) and paclitaxel. Patients received 45 mg/m2 of either PEG-Doxorubicin or SCP-Doxorubicin by an intravenous infusion over 30 minutes on day 1, followed by paclitaxel 150 mg/m2 as an intravenous infusion over three hours on day 1. We repeated treatment cycles every 28 days. Patients received a total of six cycles unless disease progression or unacceptable toxicity occurred.

Gastric Cancer (GC) is the fourth common cancer worldwide. It has a geographical distribution aff... more Gastric Cancer (GC) is the fourth common cancer worldwide. It has a geographical distribution affecting mainly the developing countries much more than the developed ones. It is an aggressive disease with poor outcome. Little breakthroughs were achieved in the treatment of GC in the last few decades. These were confined to chemotherapy and surgical techniques. The development of gastric cancer is a complex, multistep process, which involves multiple genetic and epigenetic alterations. The previous classifications of GC had limited impact on its management and prognosis. A novel molecular classification will enhance our understanding of the cancer of the stomach and it will individualize our therapy in a targeted manner for more robust results and better prognosis.
According to The Cancer Genome Atlas Project (TCGA), GC has been recently divided into 4 categories according to the molecular imprint specification. These 4 subtypes are Epstein-Barr virus positive tumors (EBVp), microsatellite instability tumors (MSI), genomically stable tumors (GS) and tumors with chromosomal instability (CIN). There is an immense diversity in the pathways where targeted and immunotherapeutic agents could treat gastric cancer. We propose a possible new treatment approach against gastric cancer guided by its genetic fingerprint.

Objectives: To determine the incidence of adverse drug events (ADEs) and assess their severity an... more Objectives: To determine the incidence of adverse drug events (ADEs) and assess their severity and preventability in four Saudi hospitals.

International journal of surgery (London, England), 2007

Registries and research on breast cancer in Arabic and developing countries are limited. We searc... more Registries and research on breast cancer in Arabic and developing countries are limited. We searched PubMed, Medline, WHO and IAEA publications, national, regional, hospital tumor registries and abstracts. We reviewed and analyzed available data on epidemiological trends and management of breast cancer in Arab countries, and compared it to current international standards of early detection, surgery and radiation therapy. Breast cancer constitutes 13-35% of all female cancers. Almost half of patients are below 50 and median age is 49-52 years as compared to 63 in industrialized nations. A recent rise of Age-Standardized Incidence Rates (ASR) is noted. Advanced disease remains very common in Egypt, Tunisia, Saudi Arabia, Syria, Palestinians and others. Mastectomy is still performed in more than 80% of women with breast cancer. There are only 84 radiation therapy centers, 256 radiation oncologists and 473 radiation technologists in all Arab countries, as compared with 1875, 3068 and 51...

Transfusion Medicine, 2007

Leukemia Research, 2009

Blood Coagulation & Fibrinolysis, 2007

Recombinant activated factor VII has been Food and Drug Administration approved to treat hemorrha... more Recombinant activated factor VII has been Food and Drug Administration approved to treat hemorrhages in hemophiliac patients with inhibitors and in acquired hemophilia patients. Recombinant activated factor VII use has also been considered for the management of uncontrolled bleeding in a number of congenital and acquired hemostatic abnormalities. The myeloproliferative disorders are a group of clonal hematologic diseases where, frequently, abnormal platelet function is considered a hallmark. This is the first case report addressing the clinical benefit of off-label use of recombinant activated factor VII in an attempt to control intractable bleeding in a patient with a myeloproliferative disorder after splenectomy.

Clinical Oncology, 2007

Oncotarget, Jan 17, 2018

Leukemia Research, 2009

Leukemia research

International journal of surgery (London, England), 2007

Transfusion Medicine, 2007

Leukemia Research, 2009

Blood Coagulation & Fibrinolysis, 2007